BMS strikes three-year cancer R&D deal with FlatironBristol-Myers Squibb has struck a three-year with Flatiron Health that aims to make cancer R&D more efficient and Share XBMS strikes three-year cancer R&D deal with Flatironhttps://pharmaphorum.com/news/bms-strikes-flatiron-deal/
Pfizer might buy BMS for $130bn – but should it?Pfizer could soon launch a multi-billion dollar bid for immunotherapy rivals Bristol-Myers Squibb. But moves into new fields Share XPfizer might buy BMS for $130bn – but should it?https://pharmaphorum.com/news/pfizer-might-buy-bms-for-130bn-but-should-it/
